Atomwise News

Featured Article
Atomwise Publishes Results from 318-Target Study Showcasing AtomNet AI Platform’s Ability to Discover Structurally Novel Chemical Matter
San Francisco, CA - April 2, 2024 – Atomwise announced today results from the AIMS (Artificial Intelligence Molecular Screen) initiative that establish the AtomNet AI Platform as a viable alternative to high-throughput screening (HTS) and verify its ability to consistently discover structurally novel chemical matter. The landmark study applied AtomNet to 318 targets through collaborations...
Read Article
August 17, 2022
Atomwise Signs Strategic Multi-Target Research Collaboration with Sanofi for AI-Powered Drug Discovery
Press Release

Agreement includes upfront payment of $20 million with the potential for $1 billion in milestone-based payments plus tiered royalties SAN FRANCISCO — August 17, 2022 — Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, today announced that it has established a strategic and exclusive research collaboration with Sanofi that will […]

Read Article
January 25, 2022
Atomwise Strengthens its Management Team, Adds Veteran Biopharma Leader David Thomson, Ph.D. as Chief Scientific Officer and Two Additional Senior Appointments
FeaturedPress Release

CSO, CFO, and GC added as technology-enabled pharma company bolsters growing management team and SAB SAN FRANCISCO, Calif. — January 25, 2022 — Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, announced today the appointment of David Thomson, Ph.D. as Chief Scientific Officer. Additional management team appointments include Jonathan Barr […]

Read Article